- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01378988
Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months
A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 Months Through <24 Months
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15224
- Children's Hospital of Pittusburgh of UPMC
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Subject is 12 months to <24 months of age at screening.
- Subject is intubated and mechanically ventilated in an intensive care setting and is anticipated to require a minimum of 6 hours of continuous IV sedation.
- Subject has adequate renal function, defined as: Serum creatinine ≤1.0 mg/dL.
- The subject's parent(s) or legal guardian(s) must voluntarily sign and date the informed consent document approved by the Institutional Review Board.
Exclusion Criteria:
Pediatric subjects with neurological conditions that prohibit an evaluation of sedation such as:
- Diminished consciousness from increased intracranial pressure
- Extensive brain surgery (surgery requiring intracranial pressure monitor)
- Diminished cognitive function per Principal Investigator (PI) discretion
- Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking agents.
- Subjects with second degree or third degree heart block unless subject has a permanent pacemaker or pacing wires are in situ.
- Subjects who have hepatic impairment as defined by a serum glutamic-pyruvic transaminase/alanine aminotransferase (SGPT/ALT) >90 U/L at the time of screening.
- Subjects who have hypotension, based on repeat assessments within 15 minutes preceding the start of study drug, defined as: Systolic blood pressure (SBP) <70 mmHg.
- Pre-existing bradycardia based on repeated assessments within 15 minutes preceding the start of study drug, defined as: Heart rate (HR) <70 bpm.
- Subject who have acute thermal burns involving more than 15 percent total body surface area.
- Subjects who have a known allergy to dexmedetomidine, midazolam or fentanyl.
- Subject who has received dexmedetomidine within 15 hours prior to the start of study drug.
- Subjects with a life expectancy that is <72 hours.
- Subjects that are expected to have hemodialysis (continuous hemofiltration), peritoneal dialysis or extracorporeal membrane oxygenation (ECMO) treatments within 48 hours prior to the start of study drug or during the duration of the study.
- Subjects who have been treated with α-2 agonists/antagonists within 2 weeks.
- Subjects with a spinal cord injury above T5 (5th Thoracic Vertebra).
- Subjects who have received another investigational drug as part of an investigational drug study within the past 30 days.
- Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of this clinical study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Dose level 1
Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
|
For sedation according to protocol
|
Kokeellinen: Dose level 2
Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
|
For sedation according to protocol
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Area Under the Plasma Concentration-time Curve (AUC0-∞)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Area under the plasma concentration-time curve of dexmedetomidine at 0 to Infinity hours
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Observed Peak Plasma Concentration (Cmax)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Maximum observed concentration of dexmedetomidine in plasma
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Steady State Concentration (Css)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Concentration of dexmedetomidine at steady state in plasma
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Terminal Elimination Half-life (t1/2)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Terminal elimination half-life of dexmedetomidine.
Half-life is the time required for plasma concentration of the drug to decrease by 50%.
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Time to Reach Maximum Plasma Concentration (Tmax)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Observed time to reach maximum plasma concentration of dexmedetomidine, expressed in hours
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Weight-Adjusted Plasma Clearance (CLw)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Weight-Adjusted Plasma Clearance of dexmedetomidine after intravenous administration.
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Plasma Clearance (CL)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Clearance of dexmedetomidine after intravenous administration.
Clearance is the rate at which the drug is removed from the plasma after the dose.
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Volume of Distribution (Vd)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Volume of distribution of dexmedetomidine after intravenous administration.
Volume of distribution measures how much the drug spreads through the body after the dose.
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Weight-Adjusted Volume of Distribution (Vdw)
Aikaikkuna: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Weight-Adjusted Volume of distribution of dexmedetomidine after intravenous administration.
|
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
|
Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score
Aikaikkuna: Prior to loading dose and every hour during the maintenance infusion; within 5 minutes after any fentanyl administration during DEX infusion or every 4 hours in case of continuous fentanyl infusion; within 5 minutes prior and after titration of fentanyl
|
FLACC scale is a 5 category observational measure to assess pediatric pain on face, legs, activity, cry and consolability.
Responses in each category are scored between 0 to 2 (0 = normal, relaxed to 2 = upset, rigid), for a maximum total score of 10.
|
Prior to loading dose and every hour during the maintenance infusion; within 5 minutes after any fentanyl administration during DEX infusion or every 4 hours in case of continuous fentanyl infusion; within 5 minutes prior and after titration of fentanyl
|
Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period
Aikaikkuna: During the treatment (6 to 24 hours)
|
The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper physical stimuli); Score 4 (unarousable). The UMSS scores obtained just prior the loading dose (LD) and 5 and 10 minutes during LD; 0, 5, 10, 15, 30, and 60 minutes and thereafter every 4 hours of the maintenance infusion; within 5 minutes of obtaining each pharmacokinetic sample; within 5 minutes prior and after any midazolam rescue during dexmedetomidine infusion period. |
During the treatment (6 to 24 hours)
|
Number of Subjects Who Received Rescue Medication for Sedation and Analgesic
Aikaikkuna: During the treatment (6 to 24 hours)
|
Participants who received rescue medication midazolam for sedation and/or fentanyl for analgesic during study drug Infusion
|
During the treatment (6 to 24 hours)
|
Yhteistyökumppanit ja tutkijat
Tutkijat
- Päätutkija: Constantinos Chrysostomou, MD, Children's Hospital of Pittusburgh of UPMC
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Huumeiden fysiologiset vaikutukset
- Adrenergiset aineet
- Neurotransmitterit
- Farmakologisen vaikutuksen molekyylimekanismit
- Keskushermostoa lamaavat aineet
- Ääreishermoston aineet
- Analgeetit
- Aistijärjestelmän agentit
- Analgeetit, ei-huumeet
- Adrenergiset alfa-2-reseptoriagonistit
- Adrenergiset alfa-agonistit
- Adrenergiset agonistit
- Hypnoottiset ja rauhoittavat lääkkeet
- Deksmedetomidiini
Muut tutkimustunnusnumerot
- DEX-11-01
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Kipu
-
Alanya Alaaddin Keykubat UniversityValmisSterilointi, tubal | Visual Analog Pain Scale
-
Korea University Anam HospitalKorea UniversityValmisKivun mittaus | Visual Analog Pain Scale
-
Turkish Ministry of Health, Kahramanmaras Provincial...Rekrytointi
-
Fujian Cancer HospitalEi vielä rekrytointiaHawthorn Red Combined Refractory Cancer Pain
-
Sobet AGLa Tour Hospital; Klinikum Klagenfurt am Wörthersee; Krankenhaus der Elisabethinen... ja muut yhteistyökumppanitRekrytointiMyofascial Pain Syndrome - Alaselkä | Myofascial Pain Syndrome - Niska | Myofascial Pain Syndrome - jännityspäänsärkyItävalta, Sveitsi
-
Ankara UniversityValmisKivun mittaus | Visual Analogue Pain ScaleTurkki
-
Yuzuncu Yıl UniversityValmisMyofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelTurkki
-
East Carolina UniversityPeruutettu
-
Washington University School of MedicinePeruutettuBruksismi | Temporomandibulaariset nivelsairaudet | Temporomandibulaarinen nivelen toimintahäiriö | Myofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelYhdysvallat
-
Quiropraxia y EquilibrioUniversidad Nacional Andres BelloValmisMyofascial Trigger Point Pain (MTrP)Chile